Rigel Pharmaceuticals (RIGL) Raw Materials (2021 - 2026)

Rigel Pharmaceuticals has reported Raw Materials for 6 years, with the latest figure at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials rose 218.2% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.4 million (up 218.2% YoY), and the FY2025 full-year result was $4.5 million, up 319.13% from the prior year.
• Raw Materials for Q1 2026 stood at $3.4 million, down from $4.5 million in the prior quarter.
• The five-year high for Raw Materials was $9.6 million in Q2 2025, with the low at $1.1 million in Q4 2024.
• Average Raw Materials over 5 years is $4.4 million, with a median of $4.6 million recorded in 2022.
• Year-over-year, Raw Materials tumbled 76.63% in 2024 and jumped 348.76% in 2025.
• Tracing RIGL's Raw Materials over 5 years: stood at $4.6 million in 2022, then grew by 1.19% to $4.6 million in 2023, then plunged by 76.63% to $1.1 million in 2024, then soared by 319.13% to $4.5 million in 2025, then declined by 24.08% to $3.4 million in 2026.
• The last three Raw Materials figures came in at $3.4 million (Q1 2026), $4.5 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.

Peer Comparison